Certainly agree, there's something going on with OWS, Nader eluted to that fact that they were talking. I feel the OWS PR dropping soon, no doubt. This drug has way to many positives!
I actually EXPECT OWS news, howard. The 75% interim review I think is a tip-off that the OWS statistician has reviewed the unblinded Phase III interim data prepared by the DSMB and reviewed by the FDA statistician.
Market Data 
Markets 
AI
